ZYZiyu Yang

Ziyu Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ziyu Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Anthony Wayne Orr

    Department of Pathology and Translational Pathobiology, LSU Health Shreveport, Shreveport, USA

    1 shared publication
  • Brian G. Coon

    Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, USA

    1 shared publication
  • Carlos Fernández-Hernando

    Vascular Biology and Therapeutics Program, Yale University School of Medicine

    1 shared publication
  • Divyesh Joshi

    Section of Cardiovascular Medicine, Yale Cardiovascular Research Center, Department of Internal Medicine, School of Medicine, Yale University

    1 shared publication
  • Emily Meredith

    Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, USA

    1 shared publication
  • Hanqiang Deng

    College of Intelligence Science and Technology, National University of Defense Technology, Changsha 410073, China

    1 shared publication

Latest Publications

  • Open Access

    Endothelial γ-protocadherins inhibit KLF2 and KLF4 to promote atherosclerosis

    by Divyesh Joshi, Brian G. Coon, Raja Chakraborty, Hanqiang Deng, Ziyu Yang, Muhammad Usman Babar, Pablo Fernandez-Tussy, Emily Meredith, John Attanasio, Nikhil Joshi, et al.

    Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide. Laminar shear stress from blood flow, sensed by vascular endothelial cells, protects from ASCVD by upregulating the transcription factors KLF2 and KLF4, which induces an anti-inflammatory program that promotes vascular resilience. Here we identify clustered γ-protocadherins as therapeutically targetable, potent KLF2 and KLF4 suppressors whose upregulation contributes to ASCVD. Mechanistic studies show that γ-protocadherin cleavage results in translocation of the conserved intracellular domain to the nucleus where it physically associates with and suppresses signaling by the Notch intracellular domain. γ-Protocadherins are elevated in human ASCVD endothelium; their genetic deletion or antibody blockade protects from ASCVD in mice without detectably compromising host defense against bacterial or viral infection. These results elucidate a fundamental mechanism of vascular inflammation and reveal a method to target the endothelium rather than the immune system as a protective strategy in ASCVD.